Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual’s immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, the treatment can cause serious side effects. New research led by investigators at the Mass General Brigham Cancer Institute , the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute has shown that patients’ inherited genetic makeup can influence whether they benefit from CAR-T cell therapy or experience toxicity from the treatment. The results are published in Science Immunology .
“These findings have important implications for understanding how CAR-T cells behave in patients since each CAR-T cell product is unique to the person from whom it is manufactured, unlike all prior forms of therapy, which are identical across patients,” said lead author Mark B. Leick, MD, an oncologist at the Mass General Brigham Cancer Institute.
For the study, Leick and his colleagues sequenced the entire genomes of more than 200 patients with aggressive lymphoma from two major clinical trials of CAR-T cell therapy. In one of the trials, patients with T cells with variants that silenced the STXBP2 gene tended to experience toxicity related to CAR-T cell therapy. Also, donor T cells engineered to lack STXBP2 and/or express these STXBP2 silencing variants triggered inflammation.
In both clinical trials, variants in the ADAMTSL3 gene correlated with protection from treatment-related toxicity, and variants in the PTPN22 gene were strongly associated with enhanced CAR T-cell expansion, which correlates with effective therapy.
The results suggest that variants in these different genes can shape the safety and therapeutic activity of CAR-T cell and other immune cell therapies.
“This may have implications for identifying the right donor for CAR-T cells, where a single donor can provide T cells for hundreds of patients, and for the design of augmented CAR-T cells, based on a deeper understanding of how human genetic variation impacts CAR-T cell behavior,” said co-senior author Marcela Maus, MD, PhD, the Paula J. O'Keeffe Endowed Chair of the Mass General Brigham Cancer Institute and the Director of the Cellular Immunotherapy Program.
Authorship: In addition to Leick and Maus, authors include Baihe Sun, Filippo Birocchi, Kathleen M.E. Gallagher, Alexandra Bratt, Seunghun Han, Grace Martin, Harrison J. Silva, Rebecca C. Larson, Tyler M. Chinsky, Hoyin Chu, Christopher R. Reilly, Michael C. Kann, Bryan D. Choi, Sabrina Camp, Riaz Gillani, Merle Phillips, Tamina Kienka, Stefanie R. Bailey, Charlotte E. Graham, Max Jan, Nicholas S. Moore, Nora Horick, Justin Budka, Simone Filosto, Chad M. Williams, Ali Hosseini Rad, Rhine R. Shen, Eliezer Van Allen, and Saud AlDubayan.
Paper cited: Leick MB et al. “Genomic correlates of clinical CAR-T cell activity” Science Immunology DOI: 10.1126/sciimmunol.aef4134
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
Science Immunology
Experimental study
People
Genomic correlates of clinical CAR T cell activity
24-Jul-2026
Budka, Filosto, and Shen are Kite Pharma employees. Maus is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (MGH; some licensed to ProMab, Luminary, and Altido Therapeutics) and University of Pennsylvania (some licensed to Novartis); receives grant/research support from Bristol Myers Squibb (BMS), Kite Pharma, Miltenyi, and Sobi; holds equity in Altido Therapeutics, Caronilex, and Umoja BioPharma; is on the board of directors of Umoja BioPharma; is a compensated consultant for A2 Biotherapeutics, Alexion, Astellas, AstraZeneca, BMS, Cabaletta Bio, Chugai, Healio, KSQ Therapeutics, Lumicks, and TriaCyte. Maus’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict-of-interest policies. Choi, Maus, and Lieck are inventors of patents related to the use of engineered cell therapies. Choi received commercial research grants from ACEA Biosciences. Choi reports financial interest in and consulting for Altido Therapeutics, Inc., which is developing CAR T cells as therapeutics for multiple indications based on the CAR-TEAM technology developed at the MGH Cancer Center. These interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham, in accordance with their conflict of interest policies. Gillani has equity in Moderna, Pfizer, and Vertex Pharmaceuticals. All other authors declare that they have no competing interests.